董事长致词：
成都云克药业有限责任公司前身为中国核动力研究设计院同位素应用研究所，是以研究核素治疗药物为主，带动其他核技术诊疗产品研究的高科技创新型企业，在全国核素药物服务领域，位列前三。
我们将不断提高综合科研能力和技术水平，培植核心竞争力，推进科技、管理、体制和运行机制创新，培育独具特色的云克药业企业文化，以蓬勃向上的姿态，迎接挑战，向国际一流核技术服务公司迈进，为我国核素诊疗事业的发展勇攀高峰，再创辉煌。在此，我代表云克药业全体职工，向所有关心和支持我公司工作的各级领导、国内外同行和朋友表示衷心的感谢并致以美好的祝愿，让我们加强交流与合作，携手奋进，共创光辉灿烂的明天！
成都云克药业有限责任公司
董事长：李明起
Message From the President:
Chengdu Yunke Pharmaceutical Co.,Ltd.(CYPC), reorganized from the Chengdu Isotope Application Institute of the Nuclear Power Institute of China (NPIC). CYPC is a high-tech innovational enterprise which majors in the researching the drug of radionuclidic therapy, and brings along other diagnostic nuclear medicine and therapeutic nuclear medicine. Currently, the CYPC is the third in vivo radiopharmaceuticals supplier.
We will continuously enhance our comprehensive scientific research capabilities and technical level, cultivate key competitive ability, promote the innovation in science and technology, management, system organization and operation mechanism and develop the culture having special characteristics of CYPC, accept the challenges with a flourishing attitude, march towards an international first class institute and bravely scale the height and create resplendence again for the development of nuclear physic career.
On behalf of staff of CYPC,I would like to extend our cordial thanks and nice greetings to the leaders of different ranks and the colleagues and friends home and abroad who have given concerns and supports to our work. Let’s strengthen the exchanges and cooperation, create a brilliant future together.
President of CYPC: LI Mingqi
